Nutriband (NASDAQ:NTRB) Posts Earnings Results

Nutriband (NASDAQ:NTRB) announced its earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, Zacks reports. Nutriband had a negative return on equity of 118.33% and a negative net margin of 403.98%.

Nutriband Price Performance

Nutriband stock traded up $0.02 during mid-day trading on Thursday, reaching $3.43. 4,644 shares of the company were exchanged, compared to its average volume of 12,155. The company has a fifty day simple moving average of $3.75 and a 200-day simple moving average of $4.19. Nutriband has a 12 month low of $3.21 and a 12 month high of $11.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.36 and a quick ratio of 6.21. The firm has a market cap of $41.70 million, a PE ratio of -1.32 and a beta of 1.90.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Nutriband presently has an average rating of “Reduce”.

Hedge Funds Weigh In On Nutriband

An institutional investor recently raised its position in Nutriband stock. Vanguard Group Inc. boosted its stake in shares of Nutriband Inc. (NASDAQ:NTRB) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 202,738 shares of the company’s stock after acquiring an additional 3,111 shares during the period. Vanguard Group Inc. owned 1.68% of Nutriband worth $1,429,000 at the end of the most recent reporting period. 19.70% of the stock is owned by institutional investors.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.